83-5964-37　［取扱停止］CD19/CD3, Blinatumomab Biosimilar (CD19, CD3E) 100ug　591717

特徴

• Blinatumomab is a BiTE-class (bi-specific T-cell engagers) constructed monoclonal antibody indicated for the treatment of Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).
• Blinatumomab is manufactured by Amgen Inc.
• and marketed under the brand Blincyto™.
• Blinatumomab was approved in December 2014 under the FDA’s accelerated approval program which allows approval of a drug to treat a serious or life-threatening disease based on clinical data showing the drug has an effect on a surrogate endpoint reasonably likely to predict clinical benefit to patients.
• Applications:Suitable for use in Functional Assays.
• Other applications not tested.
• Recommended Dilution:Optimal dilutions to be determined by the researcher.
• Storage and Stability:May be stored at 4℃ for short-term only.
• Aliquot to avoid repeated freezing and thawing.
• Store at -20℃.
• Aliquots are stable for 12 months after receipt.
• For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.